Loading organizations...
Medilink Therapeutics develops advanced drug conjugates, focusing on Antibody-Drug Conjugates (ADCs). The company utilizes proprietary technology platforms to create next-generation therapeutic candidates. These platforms enhance drug conjugate properties, improving efficacy and therapeutic windows through independent intellectual property. Their technical approach emphasizes continuous innovation in drug conjugate design.
Established in 2020, Medilink Therapeutics was founded by Tony Xue, Chairman and CEO, and Jiaqiang Cai, Co-founder, CSO, and Co-CEO. Their extensive experience in the Antibody-Drug Conjugate sector provided the crucial insight: to address unmet clinical needs by developing more targeted and effective treatments. This expertise formed the basis for the company's mission.
The company’s therapies target global patients, particularly within oncology, where improved treatment options are vital. Medilink Therapeutics aims to continually advance its drug conjugate technologies, expanding their utility into new therapeutic areas. Its vision is to deliver competitive therapeutic candidates that significantly improve patient outcomes worldwide.
Medilink Therapeutics has raised $120.0M across 2 funding rounds.
Medilink Therapeutics has raised $120.0M in total across 2 funding rounds.
Medilink Therapeutics has raised $120.0M in total across 2 funding rounds.
Medilink Therapeutics's investors include Qiming Venture Partners, LYFE Capital, Legend Capital, Loyal Valley Capital.
MediLink Therapeutics is a clinical-stage biotechnology company that develops next‑generation antibody‑drug conjugates (ADCs) using its proprietary TMALIN® tumor‑microenvironment‑activatable linker‑payload platform to improve the therapeutic window in solid tumors; the company was founded in 2020 and is headquartered in Suzhou with R&D offices in Shanghai, Boston and other locations.[2][3]
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / Biotech Landscape
Quick Take & Future Outlook
Quick take: MediLink positions itself as a platform‑first ADC developer aiming to solve a core limitation of ADC therapy—off‑tumor toxicity and heterogeneity—by deploying TMALIN® linker‑payload chemistry and advancing multiple programs into the clinic and into partner pipelines; clinical readouts over the next 12–24 months will be decisive for whether the platform meaningfully shifts competitive dynamics in ADC development.[3][2][1]
Medilink Therapeutics has raised $120.0M across 2 funding rounds. Most recently, it raised $70.0M Series B in March 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2022 | $70.0M Series B | Qiming Venture Partners, LYFE Capital | Legend Capital, Loyal Valley Capital |
| Feb 1, 2021 | $50.0M Series A | Qiming Venture Partners |